An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051
Phase of Trial: Phase I/II
Latest Information Update: 24 Jan 2019
At a glance
- Drugs SRP-5051 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Sarepta Therapeutics
- 16 Jan 2019 Status changed from not yet recruiting to recruiting.
- 23 Nov 2018 Planned End Date changed from 30 Aug 2020 to 1 Nov 2020.
- 23 Nov 2018 Planned primary completion date changed from 30 Apr 2020 to 1 Nov 2020.